Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
IPO Year: 2018
Exchange: NASDAQ
Website: modernatx.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
9/13/2024 | $120.00 → $65.00 | Buy → Hold | Jefferies |
9/13/2024 | $88.00 → $70.00 | Neutral → Underweight | JP Morgan |
9/13/2024 | Outperform → Perform | Oppenheimer | |
8/28/2024 | $82.00 | Reduce → Hold | HSBC Securities |
8/7/2024 | $85.00 → $80.00 | Sell → Hold | Deutsche Bank |
8/5/2024 | $125.00 → $90.00 | Outperform → Sector Perform | RBC Capital Mkts |
2/26/2024 | $75.00 → $86.00 | Hold → Reduce | HSBC Securities |
1/2/2024 | $142.00 | Perform → Outperform | Oppenheimer |
11/29/2023 | $82.00 | Hold | Canaccord Genuity |
11/3/2023 | $89.00 → $69.00 | Reduce → Hold | HSBC Securities |
8-K - Moderna, Inc. (0001682852) (Filer)
8-K - Moderna, Inc. (0001682852) (Filer)
10-Q - Moderna, Inc. (0001682852) (Filer)
8-K - Moderna, Inc. (0001682852) (Filer)
144 - Moderna, Inc. (0001682852) (Subject)
144 - Moderna, Inc. (0001682852) (Subject)
8-K - Moderna, Inc. (0001682852) (Filer)
144 - Moderna, Inc. (0001682852) (Subject)
144 - Moderna, Inc. (0001682852) (Subject)
144 - Moderna, Inc. (0001682852) (Subject)
4 - Moderna, Inc. (0001682852) (Issuer)
3 - Moderna, Inc. (0001682852) (Issuer)
4 - Moderna, Inc. (0001682852) (Issuer)
4 - Moderna, Inc. (0001682852) (Issuer)
4 - Moderna, Inc. (0001682852) (Issuer)
4 - Moderna, Inc. (0001682852) (Issuer)
4 - Moderna, Inc. (0001682852) (Issuer)
4 - Moderna, Inc. (0001682852) (Issuer)
4 - Moderna, Inc. (0001682852) (Issuer)
4 - Moderna, Inc. (0001682852) (Issuer)
For Immediate Release: November 30, 2020 The U.S. Food and Drug Administration has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Dec. 17 to discuss the request for emergency use authorization (EUA) for a COVID-19 vaccine from Moderna, Inc. “In keeping with the FDA’s commitment to ensuring full transparency, dialogue and efficiency, the Vaccines and Related Biological Products Advisory Comm
SC 13G/A - Moderna, Inc. (0001682852) (Subject)
SC 13G/A - Moderna, Inc. (0001682852) (Subject)
SC 13G/A - Moderna, Inc. (0001682852) (Subject)
SC 13G/A - Moderna, Inc. (0001682852) (Subject)
SC 13G/A - Moderna, Inc. (0001682852) (Subject)
SC 13G/A - Moderna, Inc. (0001682852) (Subject)
SC 13G/A - Moderna, Inc. (0001682852) (Subject)
SC 13G/A - Moderna, Inc. (0001682852) (Subject)
SC 13G/A - Moderna, Inc. (0001682852) (Subject)
SC 13G/A - Moderna, Inc. (0001682852) (Subject)
CAMBRIDGE, Mass., Oct. 3, 2024 /PRNewswire/ -- Invaio Sciences, a Flagship Pioneering bioplatform company focused on accelerating the leap to nature-positive agriculture, today announced the appointment of André Andonian as the new Chairman of its Board of Directors. Robert Berendes has decided to step down after serving as Chairman of the Board since 2019 and will continue to serve on the board of Invaio. Andonian is Chair of Asia Pacific and Strategic Advisor at Flagship Pioneering, where he and Ignacio Martinez are responsible partners for Invaio. He is also Senior Partner
Organizations Plan to Jointly Advance Breakthrough Solutions in Human Health and Sustainability, Drive Research Collaboration, Entrepreneurship and Accelerate Talent Development SINGAPORE, Oct. 2, 2024 /PRNewswire/ -- The Agency for Science, Technology and Research (A*STAR), Singapore's lead public sector R&D agency, and Flagship Pioneering, the bioplatform innovation company, today announced plans to collaborate to advance health and sustainability outcomes in Singapore and the broader Asia Pacific region. In this collaboration, A*STAR and Flagship will jointly commit up to SGD100 million over the next five years.
Hussain brings more than 35 years of commercial leadership and operating experience in healthcare, most recently serving as CEO of Vifor PharmaAs former Global President of GSK, Pharmaceuticals and Vaccines, Hussain brings significant global vaccine commercialization experience in emerging and mature markets, along with significant Board of Directors expertise CAMBRIDGE, MA / ACCESSWIRE / October 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that Abbas Hussain, former Chief Executive Officer of Vifor Pharma, has joined Moderna's Board of Directors, effective October 2, 2024."As Moderna accelerates our global commercialization efforts, Abbas is a tremendous addition to our Board," sai
CAMBRIDGE, MA and TAIPEI, TAIWAN / ACCESSWIRE / September 30, 2024 / Moderna, Inc. (NASDAQ:MRNA) and Cenra Healthcare, the sales and marketing arm of Cenra Inc., today announced that the companies have entered into a joint agreement regarding the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Taiwan, including Moderna's COVID-19 vaccine, Spikevax®.Under the agreement, Moderna will manufacture and distribute its mRNA respiratory vaccines. Cenra Healthcare will engage in promotion and execute medical education activities to ensure broad access to Moderna's mRNA respiratory portfolio across Taiwan. The agreement has an initial term until July 31, 2027, and no further details on
CAMBRIDGE, MA / ACCESSWIRE / September 30, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first participant in the U.S. has been dosed in the Nova 301 Trial, a pivotal Phase 3 randomized clinical trial evaluating the efficacy, safety, and immunogenicity of an investigational norovirus vaccine, mRNA-1403. Global recruitment for the Nova 301 trial has also begun."Norovirus is a significant public health concern that affects millions of people worldwide each year, leading to severe symptoms and, in some cases, hospitalization," said Stéphane Bancel, CEO of Moderna. "By advancing our investigational norovirus vaccine into a pivotal Phase 3 trial, we are one step closer to potentiall
Mirai's machine intelligence-based, open platform unlocks delivery to any tissue and cell type through rapid, iterative learning of in vivo tested chemistries Co-optimization of cargo design and manufacturing ensure the best possible medicine and manufacturing strategy for each new program Company emerges with an initial commitment of $50 million from Flagship Pioneering CAMBRIDGE, Mass., Sept. 26, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today unveiled Mirai Bio, a company pioneering the first open end-to-end platform for the biotech industry to enable the co-creation of fully optimized genetic medicines. Mirai's machine intelligence-based, open platform
SPIKEVAX® is the first updated COVID-19 vaccine authorized in Canada for 2024-2025, offering a timely solution to help protect Canadians this fall and winter season.Moderna will promptly begin delivery of updated COVID-19 vaccines to the Public Health Agency of Canada, so there is robust supply available in time for provincial and territorial vaccination campaigns. CAMBRIDGE, MA / ACCESSWIRE / September 17, 2024 / Moderna Inc (NASDAQ:MRNA) today announced that Health Canada has authorized its updated COVID-19 vaccine, SPIKEVAX® KP.2 variant, to help prevent COVID-19 in individuals six months of age and older. Moderna's updated COVID-19 vaccine targets the KP.2 sub-lineage of SARS-CoV-2. With
Focuses on ten product approvals through 2027Expects to submit next-generation COVID vaccine for approval in 2024Expects to submit flu/COVID combination vaccine for approval in 2024Announces positive Phase 3 results for its RSV vaccine for high-risk adults aged 18 to 59; expects to submit sBLA for U.S. approval in 2024Announces positive Phase 3 results for its standalone flu vaccine for adults aged 65 and older relative to high-dose licensed comparatorAnnounces norovirus vaccine advances into Phase 3 study, bringing the total of non-respiratory pivotal stage programs to five, across oncology, rare diseases and first-in-class vaccinesImplements portfolio prioritization and cost efficiencies t
Building on successful pre-clinical in vivo CAR-M data in oncology, the companies will develop in vivo CAR-M for autoimmune diseases Moderna nominated two autoimmune disease targets under the collaboration Carisma is eligible to receive milestones and royalty payments PHILADELPHIA, Sept. 10, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (NASDAQ:CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the expansion of its in vivo chimeric antigen receptor macrophage and monocyte (together, "CAR-M") collaboration with Moderna, Inc. (NASDAQ:MRNA) to include the nomination of two targets for
Milestone marks a significant step toward producing mRNA vaccines in Canada by 2025 CAMBRIDGE, MA / ACCESSWIRE / September 9, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that its manufacturing facility in Laval, Quebec, has been granted a Drug Establishment License (DEL) from Health Canada. This certification affirms the facility's compliance with rigorous safety and quality standards, authorizing it to produce drug substance. This key milestone enables Moderna's Canadian manufacturing site to become fully operational, bringing the company closer to ensuring a reliable and onshore supply of mRNA vaccines within Canada.With the DEL in place, the facility will proceed with the final qua
Moderna (NASDAQ:MRNA) has outperformed the market over the past 5 years by 42.19% on an annualized basis producing an average annual return of 54.8%. Currently, Moderna has a market capitalization of $45.66 billion. Buying $1000 In MRNA: If an investor had bought $1000 of MRNA stock 5 years ago, it would be worth $8,701.97 today based on a price of $119.13 for MRNA at the time of writing. Moderna's Performance Over Last 5 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and revie
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. Here's the list of options activity happening in today's session: Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume BSX PUT SWEEP BEARISH 08/16/24 $75.00 $68.9K 5.5K 2.1K MRNA CALL SWEEP NEUTRAL 11/15/24 $170.00 $121.
Directors Robert Langer and Stephen Berenson will also retire from the Board.
Investors with a lot of money to spend have taken a bullish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MRNA, it often means somebody knows something is about to happen. So how do we know what these investors just did? Today, Benzinga's options scanner spotted 8 uncommon options trades for Moderna. This isn't normal. The overall sentiment of these big-money traders is split between 37% bullish and 37%, bearish. Out of all of the special opt
Whales with a lot of money to spend have taken a noticeably bearish stance on Moderna. Looking at options history for Moderna (NASDAQ:MRNA) we detected 8 trades. If we consider the specifics of each trade, it is accurate to state that 25% of the investors opened trades with bullish expectations and 75% with bearish. From the overall spotted trades, 6 are puts, for a total amount of $218,807 and 2, calls, for a total amount of $70,833. Expected Price Movements Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $110.0 to $150.0 for Moderna over the recent three months. Volume & Open Interest Trends Examining the volume and
More than half of the states in the U.S. are experiencing significant Covid-19 activity in wastewater, and President Joe Biden remains in isolation after announcing Wednesday he caught the virus for the third time. Twenty-six states are reporting either “high” or “very high” levels of the virus at various sites, according to the latest data from the Centers for Disease Control and Prevention. States with the highest levels include Arkansas, California, Florida, Maryland, Nevada, Oregon and Texas. The Biden administration no longer considers Covid-19 a public health emergency and instead treats it as a routine respiratory virus to be prevented through an annual vaccination campaign,
The European Commission faced criticism from Europe’s second-highest court regarding transparency issues surrounding COVID-19 vaccine contracts from four years ago. This scrutiny comes on the eve of a crucial vote on Commission head Ursula von der Leyen‘s reelection bid. Some European lawmakers have been vocal about their dissatisfaction with how the Commission handled its multibillion-euro contracts, particularly its failure to disclose text messages between von der Leyen and Pfizer Inc (NYSE:PFE) CEO Albert Bourla regarding one of the agreements. In 2022, a Pfizer executive “categorically” ruled out that the pharma giant’s chief executive agreed on the European COVID-19 contract v
The Nasdaq 100 closed higher by more than 100 points on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company's prospects or that they view the stock as being overpriced. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision. Below is a look at a few recent notable insider sales. For more, check out Benzinga’s insider transactions platform. DICK’S Sporting Goods The Trade: DICK’S Sporting Goods, Inc. (NYSE:DKS) Director Desiree Ralls-Morrison sold a total of 3
Avian influenza, also known as bird flu, has public health officials on alert after it spread to an unprecedented number of cows in the U.S. this year and led to positive tests of the virus in four U.S. dairy workers so far this year. A severe variant of the H5N1 strain infected animals ranging from alpacas to house cats worldwide since 2020 and caused lethal outbreaks in commercial poultry, but this is the first year it has infected cows, Reuters reported. Humans have contracted different bird flu strains in Australia and Mexico, while different H5 subtypes have also shown up in other parts of the world including China and Cambodia. Most of the human cases have come from exposure t
In a recent development, Flagship Pioneering, the venture capital firm known for backing Moderna (NASDAQ:MRNA) has successfully secured a whopping $3.6 billion in funding. What Happened: Flagship Pioneering has raised $2.6 billion for its eighth fund and an additional $1 billion for parallel funds. These parallel funds will be invested in specific sectors such as diagnostics or therapeutics. The venture firm is also planning to raise more funds for its eighth fund later this year. The funds are intended to launch a series of new biotech companies that will harness the power of generative artificial intelligence for drug discovery, The Financial Times reported on Wednesday. Noubar Afeya
Reports second quarter revenues of $241 million, GAAP net loss of $1.3 billion and GAAP EPS of $(3.33)Updates 2024 financial framework and revises expectations for product sales to $3.0 to $3.5 billionReceived U.S. FDA approval for RSV vaccine, mRESVIA, and began shipping in July; received EMA positive opinion in JuneAnnounced positive Phase 3 data for combination vaccine against influenza and COVID-19Announced positive Phase 3 data for next-generation COVID-19 vaccine CAMBRIDGE, MA / ACCESSWIRE / August 1, 2024 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the second quarter of 2024."During the second quarter, we marked the approval of our
CAMBRIDGE, MA / ACCESSWIRE / July 10, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 1, 2024 to report its second quarter 2024 financial results, and provide a corporate update.A live webcast of the call will be available under "Events and Presentations" in the Investors section of the Moderna website.Webcast: https://investors.modernatx.comThe archived webcast will be available on Moderna's website approximately two hours after the conference call and will be available for one year following the call.About ModernaModerna is a leader in the creation of the field of mRNA medicine. Through the advance
Reports first quarter revenues of $167 million, GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)Prepares for launches of RSV vaccine and Spikevax® 2024-2025 formula; reaffirms 2024 expected product sales of approximately $4 billionInitiated three new clinical studies evaluating Moderna's investigational individualized neoantigen therapy in combination with Merck's Keytruda® for treatment of patients with bladder cancer, kidney cancer and cutaneous squamous cell carcinomaAdvanced three new vaccine programs (Epstein-Barr virus, Varicella-Zoster virus, norovirus) toward Phase 3 clinical trials as announced at Vaccines Day investor eventCAMBRIDGE, MA / ACCESSWIRE / May 2, 2024 / Mod
CAMBRIDGE, MA / ACCESSWIRE / April 17, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 2, 2024 to report its first quarter 2024 financial results, and provide a corporate update.A live webcast of the call will be available under "Events and Presentations" in the Investors section of the Moderna website.Webcast: https://investors.modernatx.comThe archived webcast will be available on Moderna's website approximately two hours after the conference call and will be available for one year following the call.About ModernaModerna is a leader in the creation of the field of mRNA medicine. Through the advancemen
Posts fourth quarter revenues of $2.8 billion, GAAP net income of $217 million and GAAP diluted EPS of $0.55Reports full-year revenues of $6.8 billion, GAAP net loss of $(4.7) billion and GAAP diluted EPS of $(12.33); loss primarily driven by mostly non-cash charges of $3.7 billion related to resizing and a tax valuation allowanceReaffirms 2024 expected product sales of approximately $4 billionExpects regulatory approvals for its investigational RSV vaccine for older adults beginning in first half of 2024, and anticipates additional key milestones from its late-stage pipeline this yearCAMBRIDGE, MA / ACCESSWIRE / February 22, 2024 / Moderna, Inc. (NASDAQ:MRNA) today reported financial result
CAMBRIDGE, MA / ACCESSWIRE / February 1, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, February 22, 2024 to report its fourth quarter and full year 2023 financial results, and provide a corporate update.A live webcast of the call will be available under "Events and Presentations" in the Investors section of the Moderna website.Webcast: https://investors.modernatx.comThe archived webcast will be available on Moderna's website approximately two hours after the conference call and will be available for one year following the call.About ModernaModerna is a leader in the creation of the field of mRNA medicine.
Third quarter 2023 revenues of $1.8 billion; Company expects 2023 revenues of at least $6 billionSpikevax U.S. market share to date increased to 45% from 36% in 2022Company anticipates 2024 revenue of approximately $4 billion and return to growth in 2025Company has significantly improved future cost of sales by resizing its manufacturing capacity, contributing to a third quarter net loss of $3.6 billion, primarily driven by mostly non-cash charges of $3.1 billion related to resizing and a tax valuation allowanceCompany's late-stage pipeline has six Phase 3 programsCompany expects to break even in 2026 through product launches and disciplined investmentCAMBRIDGE, MA / ACCESSWIRE / November 2,
CAMBRIDGE, MA / ACCESSWIRE / October 12, 2023 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 2, 2023 to report its third quarter 2023 financial results, and provide a corporate update.A live webcast of the call will be available under "Events and Presentations" in the Investors section of the Moderna website.Webcast: https://investors.modernatx.comThe archived webcast will be available on Moderna's website approximately two hours after the conference call and will be available for one year following the call.About ModernaIn over 10 years since its inception, Moderna has transformed from a research-stage
Second quarter 2023 revenues of $0.3 billion; net loss of $1.4 billion and loss per share of $3.62Company expecting 2023 COVID-19 vaccine sales of $6 billion to $8 billion, dependent on U.S. vaccination ratesCompany submitted its investigational RSV vaccine to several regulators globally ahead of potential 2024 launchWith its partner Merck, the Company began Phase 3 trial of mRNA-4157, its individualized neoantigen therapy (INT), in combination with Keytruda®, for high-risk melanomaCAMBRIDGE, MA / ACCESSWIRE / August 3, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today reported financial results and provided business
CAMBRIDGE, MA / ACCESSWIRE / July 13, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 3, 2023 to report its second quarter 2023 financial results, and provide a corporate update.A live webcast of the call will be available under "Events and Presentations" in the Investors section of the Moderna website.Webcast: https://investors.modernatx.comThe archived webcast will be available on Moderna's website approximately two hours after the conference call and will be available for one year following the call.About ModernaIn
CAMBRIDGE, Mass., Oct. 3, 2024 /PRNewswire/ -- Invaio Sciences, a Flagship Pioneering bioplatform company focused on accelerating the leap to nature-positive agriculture, today announced the appointment of André Andonian as the new Chairman of its Board of Directors. Robert Berendes has decided to step down after serving as Chairman of the Board since 2019 and will continue to serve on the board of Invaio. Andonian is Chair of Asia Pacific and Strategic Advisor at Flagship Pioneering, where he and Ignacio Martinez are responsible partners for Invaio. He is also Senior Partner
Hussain brings more than 35 years of commercial leadership and operating experience in healthcare, most recently serving as CEO of Vifor PharmaAs former Global President of GSK, Pharmaceuticals and Vaccines, Hussain brings significant global vaccine commercialization experience in emerging and mature markets, along with significant Board of Directors expertise CAMBRIDGE, MA / ACCESSWIRE / October 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that Abbas Hussain, former Chief Executive Officer of Vifor Pharma, has joined Moderna's Board of Directors, effective October 2, 2024."As Moderna accelerates our global commercialization efforts, Abbas is a tremendous addition to our Board," sai
Former White House Top Health Security Official to Lead Flagship's Preemptive Health and Medicine Initiative CAMBRIDGE, Mass., Aug. 6, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced that globally distinguished healthcare expert, entrepreneur, and public policy leader Raj Panjabi, M.D., MPH, will join Flagship as Senior Partner. Dr. Panjabi will lead Flagship's Preemptive Health and Medicine Initiative (PH&M), which is pioneering a new field to protect, maintain, or improve people's health before they get sick. In its fifth year, the initiative is grounded in the premise that health should be accessible for all and pursues interventions that prot
Chris Schade appointed as Board ChairpersonLynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of DirectorsCAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Opera
O'Shea is a Seasoned Global Executive with more than 20 Years' Experience across the Agriculture, Food and Pharmaceutical Industries CAMBRIDGE, Mass., April 8, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Invaio Sciences, a bioplatform company accelerating the leap to nature-positive agriculture, today announced that Amy O'Shea has joined Flagship Pioneering as CEO-Partner and Invaio as Chief Executive Officer and Board Director. O'Shea is a seasoned global executive with more than 20 years' experience across the agriculture, food, and phar
Banks was Most Recently the President and CEO of Tyson Foods and has been a Board Member of Indigo since July 2022 Company Closes Financing Round at Nearly $270 Million Indigo Also Appoints Nader Bekhouche and Noubar Afeyan to Board of Directors CAMBRIDGE, Mass., Jan. 9, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Indigo Ag, an innovative leader and trusted partner in sustainable agriculture, today announced that Dean Banks will join Flagship Pioneering as CEO-Partner and CEO of Indigo Ag, effective February 1, 2024. Banks will also continue as an Indigo board member, a role he has held since July 2022. Indigo also announced the appointments of Nader Be
Memorandum of Understanding with UK Government Outlines Areas of Cooperation CAMBRIDGE, Mass. and LONDON, Nov. 27, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today marked the official launch of its UK presence with an event co-hosted in partnership with the UK Government's Office for Life Sciences, bringing together top leaders from industry, government, and academia with a focus on breakthrough innovation. The event marked Flagship's public announcement of its strategic commitment to the UK life sciences ecosystem a week after launching Quotient Therapeutics, its first company located in both the UK and US.
CAMBRIDGE, Mass., Oct. 2, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and ProFound™ Therapeutics, a company pioneering the discovery of a vastly expanded human proteome and using its newfound insights to unlock a universe of potential new medicines, today announced that John Lepore, M.D., will join Flagship Pioneering as CEO-Partner, and ProFound as Chief Executive Officer, effective October 16, 2023. Dr. Lepore joins ProFound after 17 years at GSK where he had extensive experience leading large international R&D organizations across diverse t
ProFound™ Therapeutics, a company pioneering the discovery of a vastly expanded human proteome and using its newfound insights to unlock a universe of potential new medicines, today announced the appointment of Klaus Urbahns, Ph.D., as Chief Scientific Officer. Urbahns will lead the Company's platform and drug discovery and development efforts to advance first-in-class therapeutics leveraging the company's ProFoundry™ Platform. Urbahns brings three decades of robust drug discovery and development experience to ProFound, with a successful track record in discovering and advancing first-in-human medicines from the lab to the clinic. He joins ProFound after 13 years at Merck KGaA, where he m
CAMBRIDGE, Mass., Sept. 11, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today the appointment of Amanda Kay as Senior Partner and Chief Business Development Officer. In this role, she will be responsible for driving and supporting business development across the Flagship ecosystem, leading the effort to forge strong partnerships between Flagship companies and the biopharma industry. She will also work closely with the Pioneering Medicines unit of Flagship as we continue to invest in and grow our corporate alliance strategy. "Partner
Jefferies downgraded Moderna from Buy to Hold and set a new price target of $65.00 from $120.00 previously
JP Morgan downgraded Moderna from Neutral to Underweight and set a new price target of $70.00 from $88.00 previously
Oppenheimer downgraded Moderna from Outperform to Perform
HSBC Securities upgraded Moderna from Reduce to Hold and set a new price target of $82.00
Deutsche Bank upgraded Moderna from Sell to Hold and set a new price target of $80.00 from $85.00 previously
RBC Capital Mkts downgraded Moderna from Outperform to Sector Perform and set a new price target of $90.00 from $125.00 previously
HSBC Securities downgraded Moderna from Hold to Reduce and set a new price target of $86.00 from $75.00 previously
Oppenheimer upgraded Moderna from Perform to Outperform and set a new price target of $142.00
Canaccord Genuity initiated coverage of Moderna with a rating of Hold and set a new price target of $82.00
HSBC Securities upgraded Moderna from Reduce to Hold and set a new price target of $69.00 from $89.00 previously